Contact
searchSearch
HMP Global
Login

Bipolar Disorders

A baby resting on a mom's shoulder
News
Interpersonal Therapy Shows Promise for Perinatal Bipolar Disorder Management
05/07/2026
Maria Mantas
A pilot study found that an adapted version of Interpersonal and Social Rhythm Therapy (IPSRT) demonstrated both feasibility and high patient satisfaction across perinatal-specific challenges in pregnant women with bipolar disorder.
A pilot study found that an adapted version of Interpersonal and Social Rhythm Therapy (IPSRT) demonstrated both feasibility and high patient satisfaction across perinatal-specific challenges in pregnant women with bipolar disorder.
A pilot study found that an...
05/07/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network
A profile of a person split in half, one half teal and the other purple, with a swirl line over the head
News
Higher Risk of Premature Death Found in Bipolar II Disorder
04/07/2026
Brionna Mendoza
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is...
04/07/2026
Psych Congress Network
Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
Postpartum mother holding child
News
Postpartum Psychosis Should Be a Distinct Diagnosis, Experts Recommend
11/19/2025
Maria Mantas
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is...
11/19/2025
Psych Congress Network
Covid-19
News
COVID-19 Post-Acute Sequelae More Likely in Patients With Serious Mental Illness
11/03/2025
Jolynn Tumolo
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia,...
11/03/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network

News

A profile of a person split in half, one half teal and the other purple, with a swirl line over the head
News
Higher Risk of Premature Death Found in Bipolar II Disorder
04/07/2026
Brionna Mendoza
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is associated with significantly increased mortality, according to a large population-based cohort study published in JAMA Network Open.
Bipolar II disorder (BD-II) is...
04/07/2026
Psych Congress Network
Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
Postpartum mother holding child
News
Postpartum Psychosis Should Be a Distinct Diagnosis, Experts Recommend
11/19/2025
Maria Mantas
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is...
11/19/2025
Psych Congress Network
Covid-19
News
COVID-19 Post-Acute Sequelae More Likely in Patients With Serious Mental Illness
11/03/2025
Jolynn Tumolo
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia, bipolar disorder, or recurrent major depressive disorder have a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC) than patients without serious mental illness.
Patients with schizophrenia,...
11/03/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network
stethoscope, pills, and a brain
News
Stimulant Treatment for ADHD Associated With Psychosis and BD
09/25/2025
Maria Mantas
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.
Stimulant use for the treatment...
09/25/2025
Psych Congress Network
DNA puzzle
News
Recent Cohort Study Assesses Genetic Relationships Between Psychotic Disorders
07/23/2025
Maria Mantas
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective, delusional disorder, acute psychoses, psychosis otherwise not specified, and schizoaffective disorder do not appear to be subtypes of schizophrenia, bipolar disorder, or major depression.
From a genetic perspective,...
07/23/2025
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
A pregnant woman attends her doctor's appointment
News
Untreated Maternal MDD May Outweigh SSRI Risks in Pregnancy
08/18/2026
Brionna Mendoza
Treating MDD during pregnancy should be prioritized as part of maternal and fetal health care, argued the authors of a Special Communication published in JAMA Psychiatry.
Treating MDD during pregnancy should be prioritized as part of maternal and fetal health care, argued the authors of a Special Communication published in JAMA Psychiatry.
Treating MDD during pregnancy...
08/18/2026
Psych Congress Network
a worried woman looks out a window
Research Summary
Personal Worries May Drive Mind-Wandering in Major Depression
08/14/2026
Maria Mantas
In a preregistered study of 106 adults, individuals with major depressive disorder (MDD) reported more mind-wandering than healthy controls during a continuous performance task.
In a preregistered study of 106 adults, individuals with major depressive disorder (MDD) reported more mind-wandering than healthy controls during a continuous performance task.
In a preregistered study of 106...
08/14/2026
Psych Congress Network
a man smokes a cigarette
Research Summary
Substance Use Not Robustly Linked to rTMS Response in MDD
08/13/2026
Maria Mantas
Baseline alcohol, nicotine, and cannabis use was largely not associated with antidepressant response to rTMS among patients with MDD, according to study findings.
Baseline alcohol, nicotine, and cannabis use was largely not associated with antidepressant response to rTMS among patients with MDD, according to study findings.
Baseline alcohol, nicotine, and...
08/13/2026
Psych Congress Network
US FDA sign
News
FDA Approves Oveporexton for Adults With Narcolepsy Type 1
08/06/2026
Brionna Mendoza
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved oveporexton (ORZEYFUL), a first-in-class orexin treatment for narcolepsy type 1 (NT1) in adults.
The US FDA has approved...
08/06/2026
Psych Congress Network
FDA building
FDA Approval
FDA Approves Centanafadine for Pediatric and Adult ADHD
07/27/2026
Maria Mantas
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug...
07/27/2026
Psych Congress Network
illustration of a brain
Research Summary
Repeated Low-Dose Oral Esketamine Did Not Increase BDNF in Treatment-Resistant Depression
07/21/2026
Maria Mantas
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving...
07/21/2026
Psych Congress Network
FDA approval stamp
FDA Alerts
FDA Accepts NDA for AXS-12 in Cataplexy Associated With Narcolepsy
07/16/2026
Maria Mantas
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug...
07/16/2026
Psych Congress Network
Rakesh Jain, MD, MPH
Rapid Reaction
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health
07/16/2026
Rakesh Jain, MD, MPH, RD; Maria Mantas
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds to news that Eli Lilly and Company plans to acquire AtaiBeckley Inc, expanding its presence in the emerging field of psychedelic-based treatments for depression and other psychiatric conditions.
Rakesh Jain, MD, MPH, responds...
07/16/2026
Psych Congress Network
a stethoscope, pills, and brain
Research Summary
Biobehavioral Markers May Improve Antidepressant Response in Major Depressive Disorder
07/16/2026
Maria Mantas
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both drugs.
Patients with MDD and favorable...
07/16/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
iTBS Offers Short-Term Improvement in Major Depressive Disorder
07/10/2026
Brionna Mendoza
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial...
07/10/2026
Psych Congress Network

Quizzes

a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network
Death risk increased by how much with a bipolar disorder diagnosis?
Quiz
Death risk increased by how much with a bipolar disorder diagnosis?
02/26/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/26/2024
Psych Congress Network
polygenic risk scores
Quiz
Is there an association between hospitalization frequency and polygenic risk score?
10/06/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
10/06/2022
Psych Congress Network
COVID-19 risk.
Quiz
Antipsychotic Use and COVID-19 Risk in Patients with BD and SMI
06/15/2022
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use...
06/15/2022
Psych Congress Network
Quiz
Challenges for Patients With Bipolar Disorder
01/11/2022
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey,...
01/11/2022
Psych Congress Network
Chelsie Monroe Expert Insights Quiz
Expert Insights Quiz
Distinguishing EDS From Fatigue
08/03/2026
Maria Mantas
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can...
08/03/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Treatment for Adolescent MDD
07/23/2026
Maria Mantas
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA...
07/23/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Major Depressive Disorder Insights Quiz
Evaluating Anhedonia in MDD
07/22/2026
Maria Mantas
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of anhedonia in major depressive disorder (MDD) as more than simply a loss of pleasure? Test your knowledge with this quiz!
Why should clinicians think of...
07/22/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
Patient Priorities in MDD Treatment
07/13/2026
Maria Mantas
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of...
07/13/2026
Psych Congress Network
Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Psilocybin Outcomes for MDD
06/11/2026
Brionna Mendoza
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
06/11/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use